While the approval of QDENGA is a notable development, some experts and observers are urging caution regarding its implementation. The primary concern lies in the complexity of dengue immunity, where the vaccine's performance across different serotypes and varying population health profiles remains a subject of intense scrutiny. Critics argue that relying on a vaccine might lead to a false sense of security, potentially causing a decline in essential sanitation and mosquito-control efforts.
There are also significant questions regarding the cost and accessibility of the vaccine. If the price point is too high, it may only be available to affluent segments of the population, leaving the most vulnerable communities—who are often the most exposed to mosquito-breeding environments—without protection. Ensuring equitable access will require a massive government subsidy or a carefully managed public-private partnership, neither of which has been fully detailed yet.
Furthermore, the long-term monitoring of the vaccine's impact is critical. Skeptics point out that dengue is a complex disease with unique biological challenges, and real-world data in the Indian context will be essential to confirm that the vaccine provides durable protection without unexpected side effects. There is a fear that if the rollout is rushed or if the vaccine's efficacy wanes over time, public trust in immunization programs could be undermined.
Ultimately, the success of this initiative depends on transparency and rigorous post-market surveillance. Critics emphasize that the government must remain committed to traditional prevention methods, such as water management and waste disposal, rather than viewing the vaccine as a silver bullet. Without a comprehensive strategy that addresses both the biological and socioeconomic aspects of the disease, the vaccine may not deliver the widespread relief that the public expects.